{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "epsTrailingTwelveMonths": -46.9, "sharesOutstanding": 2949270, "bookValue": -28.84, "fiftyDayAverage": 4.359, "fiftyDayAverageChange": -2.3590002, "fiftyDayAverageChangePercent": -0.5411792, "twoHundredDayAverage": 15.42625, "twoHundredDayAverageChange": -13.42625, "twoHundredDayAverageChangePercent": -0.87035084, "marketCap": 5898540, "priceToBook": -0.06934813, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "currency": "EUR", "financialCurrency": "USD", "regularMarketOpen": 2.04, "averageDailyVolume3Month": 138, "averageDailyVolume10Day": 197, "fiftyTwoWeekLowChange": 0.13999999, "fiftyTwoWeekLowChangePercent": 0.07526881, "fiftyTwoWeekRange": "1.86 - 47.4", "fiftyTwoWeekHighChange": -45.4, "fiftyTwoWeekHighChangePercent": -0.95780593, "fiftyTwoWeekLow": 1.86, "fiftyTwoWeekHigh": 47.4, "earningsTimestamp": 1682679614, "earningsTimestampStart": 1687350600, "earningsTimestampEnd": 1687782600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "firstTradeDateMilliseconds": 1532930400000, "priceHint": 4, "marketState": "REGULAR", "regularMarketChange": -0.22000003, "regularMarketTime": 1683892036, "regularMarketDayHigh": 2.04, "regularMarketDayRange": "1.99 - 2.04", "regularMarketDayLow": 1.99, "regularMarketVolume": 1225, "regularMarketPreviousClose": 2.22, "bid": 0.0, "ask": 0.0, "fullExchangeName": "Frankfurt", "regularMarketChangePercent": -9.909911, "regularMarketPrice": 2.0, "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "FRA", "shortName": "REDHILL B.S.AD 400/IL-,01", "longName": "RedHill Biopharma Ltd.", "messageBoardId": "finmb_104926324", "market": "dr_market", "symbol": "2RH0.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "21 Ha\u2019arba\u2019a Street", "city": "Tel Aviv", "zip": "6473921", "country": "Israel", "phone": "972 3 541 3131", "fax": "972 3 541 3144", "website": "https://www.redhillbio.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Dror  Ben-Asher", "age": 56, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 734594, "fmt": "734.59k", "longFmt": "734,594"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Gilead  Raday MPhil, MSc", "age": 47, "title": "Chief Operating Officer", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 445385, "fmt": "445.38k", "longFmt": "445,385"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Adi  Frish", "age": 52, "title": "Chief Corp. & Bus. Devel. Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 419502, "fmt": "419.5k", "longFmt": "419,502"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Rick D. Scruggs", "age": 62, "title": "Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 607046, "fmt": "607.05k", "longFmt": "607,046"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Micha  Ben-Chorin", "age": 53, "title": "Advisor", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 454205, "fmt": "454.2k", "longFmt": "454,205"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Razi  Ingber", "age": 38, "title": "Chief Financial Officer", "yearBorn": 1984, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mark L. Levitt M.D., Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Alexandra  Okmian", "title": "Sr. Bus. Devel. & Investor Relations Mang.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Kristin  Comer", "title": "VP, Gen. Counsel & Chief Compliance Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Rob  Jackson", "title": "Sr. VP of Sales & Marketing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}